How to Formulate a PIH Brightening Serum: Multi-Mechanism Formula | Onerchem
◆ Formulation Guide
How to Formulate a PIH Brightening Serum: Multi-Mechanism Active Selection & Complete Protocol
Post-inflammatory hyperpigmentation (PIH) is a multi-step process — and a single brightening active cannot address it effectively. This guide covers the four-node mechanism of PIH, the rationale for each active in a multi-mechanism formula, a complete ingredient list with percentages, and the processing protocol that keeps pH-sensitive actives stable through production and shelf life.
PIH mechanism — why one active is never enough
Post-inflammatory hyperpigmentation occurs when skin inflammation — from acne, eczema, trauma, or UV damage — triggers a cascade of signals that result in localised melanin overproduction. The cascade has four distinct nodes, and an effective brightening formula needs to address more than one of them.
Node 01
Inflammation Signal
Skin trauma activates plasminogen → plasmin, which releases arachidonic acid from keratinocyte membranes, driving prostaglandin E2 production and ultimately MSH upregulation.
TXA targets here
Node 02
Tyrosinase Activation
MSH binds melanocyte MC1R receptors, upregulating tyrosinase — the rate-limiting enzyme in melanin synthesis. Tyrosinase converts tyrosine to DOPA and then to DOPAquinone.
Alpha-Arbutin targets here
Node 03
Melanin Synthesis
DOPAquinone undergoes polymerisation to form eumelanin (brown-black) or pheomelanin (yellow-red). Vitamin C derivatives can reduce oxidised melanin intermediates at this stage.
3-O-EAA targets here
Node 04
Melanosome Transfer
Completed melanosomes are transferred from melanocytes to surrounding keratinocytes via dendritic contact. This transfer step determines how pigment distributes in the epidermis.
Niacinamide targets here
A formula that only inhibits tyrosinase is addressing Node 02 of a four-node cascade. The inflammation signal at Node 01 continues, the residual tyrosinase activity at Node 02 is never fully blocked, and transfer at Node 04 is untouched. Multi-mechanism coverage is the only rational approach to PIH formulation.
Active selection — four mechanisms, one formula
Tranexamic Acid (TXA)
Node 01 · Plasmin Inhibitor · Upstream Signal Interception
Mechanism
Synthetic lysine analogue — competitively blocks lysine-binding sites on plasminogen, preventing conversion to active plasmin. Interrupts the arachidonic acid → prostaglandin E2 → MSH signalling chain upstream of tyrosinase.
Use concentration
2–3% in finished formula
Based on published cosmetic use data for topical TXA
pH stability
Stable across pH 4.0–8.0 — no special pH requirement
Regulatory status
EU CosIng listed · IECIC · US cosmetic permitted CosIng ↗
Alpha-Arbutin
Node 02 · Tyrosinase Inhibitor · Enzyme-Level Blockade
Mechanism
Hydroquinone glycoside — competitively inhibits tyrosinase by occupying the copper-binding active site. Alpha stereoisomer (CAS 84380-01-8) is more stable than beta form and does not release free hydroquinone at cosmetic use concentrations.
Use concentration
1–2% in finished formula
Based on published cosmetic use data for Alpha-Arbutin
pH stability
Stable across pH 3.5–7.0 — optimal below pH 6.5
Regulatory status
EU CosIng listed (CAS 84380-01-8) · IECIC CosIng ↗
Niacinamide
Node 04 · Melanosome Transfer Inhibitor
Mechanism
Inhibits melanosome transfer from melanocytes to keratinocytes — the mechanism is not fully characterised but involves reduction of melanosome package transfer via dendritic contact pathways. Also supports skin barrier function and has anti-inflammatory properties.
Use concentration
4–5% in finished formula
Based on published cosmetic use data; above 5% may cause flushing in sensitive individuals
pH stability
Stable pH 4.5–7.0. Above pH 7.0, conversion to niacin increases over time.
Regulatory status
EU CosIng listed (CAS 98-92-0) · IECIC · FDA permitted CosIng ↗
3-O-Ethyl Ascorbic Acid
Node 03 · Melanin Reduction · Antioxidant
Mechanism
Ether derivative of Vitamin C — reduces oxidised melanin intermediates (DOPAquinone) back to colourless forms. Provides antioxidant protection against UV-triggered reactive oxygen species. Enzymatically converts to Ascorbic Acid after skin penetration.
Use concentration
2–3% in finished formula
Based on published cosmetic use data for 3-O-EAA
pH stability
Stable pH 4.0–7.5 — significantly wider range than L-Ascorbic Acid
Regulatory status
EU CosIng listed · IECIC · US cosmetic permitted CosIng ↗
Why Not L-Ascorbic Acid?
L-Ascorbic Acid (pure Vitamin C) requires pH 2.5–3.5 for stability and effective penetration — a range that is incompatible with TXA, Niacinamide, and Alpha-Arbutin in a single formula, and unnecessarily harsh for post-inflammatory skin. 3-O-Ethyl Ascorbic Acid provides comparable brightening activity at pH 5.0–6.0, enabling a stable multi-active formula without the compatibility trade-off.
Complete formula — Multi-Mechanism PIH Brightening Serum
| Ingredient (INCI) | % | Function / Notes |
|---|---|---|
| Phase A — Water Phase (ambient temperature) | ||
| Aqua (Water) | q.s. to 100 | Base — demineralised, conductivity <5 µS/cm |
| Glycerin | 4.00% | Humectant, co-solvent, processing aid |
| Sodium Hyaluronate (HMW, 1500–1800 kDa) | 0.10% | Surface hydration — disperse cold before heating. CAS 9067-32-7. |
| Sodium Hyaluronate (LMW, 10–50 kDa) | 0.05% | Penetrating hydration layer |
| Hydroxyethylcellulose (HEC) | 0.40% | Non-ionic thickener — compatible with all actives. Disperse cold, hydrate before heating. |
| Pentylene Glycol | 3.00% | Humectant, mild preservation boost, skin feel |
| Disodium EDTA | 0.05% | Metal chelation — improves stability of Vitamin C derivative |
| Phase B — Heat Phase (65°C, for HEC hydration) | ||
| — (Phase A heated to 65°C) | — | Hold at 65°C for 15 min to complete HEC hydration. Cool to below 40°C before active addition. |
| Phase C — Cool-down Actives (below 40°C) | ||
| Tranexamic Acid | 2.50% | Node 01 — upstream signal interception. Water-soluble, add directly. CAS 1197-18-8. |
| Alpha-Arbutin | 2.00% | Node 02 — tyrosinase inhibition. Confirm alpha stereoisomer on COA. CAS 84380-01-8. |
| Niacinamide | 4.00% | Node 04 — melanosome transfer inhibition + barrier support. CAS 98-92-0. |
| 3-O-Ethyl Ascorbic Acid | 2.00% | Node 03 — melanin reduction + antioxidant. Add after pH is confirmed in range 5.0–6.0. |
| Panthenol (D-Panthenol) | 1.00% | Wound healing, barrier support — supports recovery in compromised skin |
| Allantoin | 0.20% | Soothing, keratolytic at low concentration — important for post-inflammatory skin |
| Phase D — Preservation & pH (below 35°C) | ||
| Phenoxyethanol | 0.90% | Primary preservative — globally accepted, compatible with all actives in this formula |
| Ethylhexylglycerin | 0.10% | Preservation booster, skin conditioning |
| Lactic Acid (10% solution) — to pH 5.0–5.5 | q.s. | pH adjustment — target range balances all four active stability windows |
| Sodium Hydroxide (10% solution) — if needed | q.s. | pH correction upward if over-acidified |
| TOTAL | 100% | Target pH 5.0–5.5 · Target viscosity 3,000–6,000 cP · Design target: broad-spectrum PIH coverage across nodes 01–04 |
Design Target — Not a Validated Claim
The active concentrations in this formula are design targets based on published cosmetic use data. The formula has not been tested in a clinical setting. Any efficacy claims on the finished product must be supported by in-vivo or in-vitro testing appropriate to the claim and the target market's regulatory requirements before launch.
Onerchem Ingredients in This Formula
Tranexamic Acid ·
Alpha-Arbutin ·
Niacinamide ·
3-O-Ethyl Ascorbic Acid ·
D-Panthenol ·
Sodium HyaluronateSamples available for all actives. Batch-specific COA and MSDS with every order. Request samples →
Processing protocol
1
Disperse HEC and Sodium Hyaluronate in cold water
Add HEC slowly to cold demineralised water under moderate agitation. Disperse both HA grades separately first, then combine. Add Glycerin, Pentylene Glycol, and Disodium EDTA. Allow 30 minutes hydration time at ambient temperature.
🌡 20–25°C · 30 min
2
Heat to 65°C — complete HEC hydration
Slowly heat to 65°C under gentle agitation. Hold 15 minutes. Phase should be clear and uniformly viscous. Do not exceed 70°C.
🌡 65°C · 15 min hold
3
Cool to below 40°C — add actives in order
Cool under gentle agitation to below 40°C. Add in this order: Tranexamic Acid → Alpha-Arbutin → Niacinamide → Panthenol → Allantoin. Mix gently after each addition until fully dissolved. Do not add 3-O-EAA until pH is confirmed in the correct range in Step 5.
🌡 Below 40°C
4
Add preservation
Below 35°C, add Phenoxyethanol and Ethylhexylglycerin. Mix until homogeneous.
🌡 Below 35°C
5
Adjust pH to 5.0–5.5 — then add 3-O-EAA
Measure pH. Adjust with Lactic Acid (10% working solution) to pH 5.0–5.5. Confirm pH is within range before adding 3-O-Ethyl Ascorbic Acid — this active is most vulnerable to instability at incorrect pH. Once pH is confirmed, add 3-O-EAA and mix gently until dissolved. Re-check pH after addition as 3-O-EAA may affect it slightly. Final target pH 5.0–5.5.
🌡 Below 35°C · Target pH 5.0–5.5
6
QC checks
Measure: pH (5.0–5.5 ✓), viscosity (3,000–6,000 cP at 25°C ✓), appearance (clear to very slightly hazy, no particulates ✓), colour (colourless to very pale yellow — 3-O-EAA may impart slight yellow tint ✓). Fill stability samples and submit for microbial challenge testing per ISO 11930.
pH management — the critical parameter for this formula
This formula contains four actives with overlapping but not identical pH stability windows. The target range of pH 5.0–5.5 sits within all four windows simultaneously:
- Tranexamic Acid — stable pH 4.0–8.0. No constraint at pH 5.0–5.5.
- Alpha-Arbutin — stable pH 3.5–7.0. Optimal below pH 6.5. pH 5.0–5.5 is well within range.
- Niacinamide — stable pH 4.5–7.0. Above pH 7.0, conversion to niacin accelerates. pH 5.0–5.5 is optimal.
- 3-O-Ethyl Ascorbic Acid — stable pH 4.0–7.5. Most stable below pH 6.5. pH 5.0–5.5 is within the optimal window.
- Monitor pH drift on stability — Include pH measurement at T=0, 1, 3, and 6 months in your stability protocol. A pH shift above 6.0 on accelerated stability suggests formulation instability and should be investigated before launch. Use Lactic Acid for downward correction — avoid Citric Acid in formulas containing Vitamin C derivatives as citrate may compete with ascorbate chemistry.
Stability testing requirements
| Test | Condition | Duration | Key Parameters |
|---|---|---|---|
| Accelerated stability | 40°C / 75% RH | 3 months | pH ±0.3 · Viscosity ±20% · Colour stable · No precipitation |
| Freeze-thaw | 5 cycles −10°C / +25°C | — | No phase change · No visible particulates on return to room temp |
| Refrigerated | 4°C | 3 months | No gelling · No precipitation · Colour check |
| Photo-stability | UV exposure — ICH Q1B or equivalent | Per method | Colour change monitoring — 3-O-EAA is light-sensitive. Opaque packaging recommended. |
| Microbial challenge (PET) | ISO 11930 | 28 days | Category A or B compliance required before launch |
| Real-time | 25°C / 60% RH | 12–24 months | All parameters vs T=0 baseline |
Packaging Recommendation
3-O-Ethyl Ascorbic Acid is sensitive to UV exposure and will oxidise and discolour under prolonged light exposure. Airless pump or opaque packaging is strongly recommended for any formula containing a Vitamin C derivative. Clear glass or clear plastic bottles will show visible yellowing within weeks under retail lighting conditions — this is oxidative degradation, not a quality defect, but it is cosmetically problematic and may indicate loss of activity.
Product Page · Brightening Series
Tranexamic Acid (CAS 1197-18-8) — HPLC ≥98%, batch COA, EU CosIng compliant
View Product
→
Frequently asked questions
PIH involves four sequential nodes — inflammation signal, tyrosinase activation, melanin synthesis, and melanosome transfer. The most effective approach is multi-mechanism coverage: Tranexamic Acid (2–3%) at Node 01, Alpha-Arbutin (1–2%) at Node 02, 3-O-EAA (2–3%) at Node 03, and Niacinamide (4–5%) at Node 04. Each active addresses a different step — the combination provides coverage that no single ingredient can match. Concentrations are based on published cosmetic use data; efficacy claims require in-vivo validation specific to your finished formula.
pH 5.0–5.5 is the optimal target for this four-active formula. This range sits within the stability windows of all four actives simultaneously: TXA (pH 4.0–8.0), Alpha-Arbutin (pH 3.5–7.0), Niacinamide (pH 4.5–7.0), and 3-O-EAA (pH 4.0–7.5). It is also appropriate for post-inflammatory skin, which benefits from a mild acidic formula close to physiological skin surface pH.
TXA is a synthetic lysine analogue that works upstream of tyrosinase — it blocks plasminogen activation, interrupting the inflammation-driven signalling cascade before it reaches the melanocyte. This upstream Node 01 mechanism is distinct from and complementary to tyrosinase inhibitors (Alpha-Arbutin, Kojic Acid) which act at Node 02. TXA is also water-soluble, colourless, pH-tolerant, and formulation-friendly — making it one of the most practically useful brightening actives available.
Yes. Alpha-Arbutin (CAS 84380-01-8) is listed in the EU CosIng database and permitted under Regulation (EC) No 1223/2009. It is not on the restricted or prohibited lists. Confirm the alpha stereoisomer on the supplier COA — Alpha-Arbutin and Beta-Arbutin are different compounds with different regulatory and stability profiles. CosIng database: ec.europa.eu/cosing.
L-Ascorbic Acid requires pH 2.5–3.5 for stability and penetration — incompatible with TXA, Niacinamide, and Alpha-Arbutin in a single formula, and unnecessarily harsh for post-inflammatory skin. 3-O-EAA is stable across pH 4.0–7.5 and can be co-formulated with all other actives at pH 5.0–5.5. The trade-off: 3-O-EAA has less published clinical data than pure Vitamin C, though in-vitro data supports brightening activity. Efficacy claims for finished products require specific in-vivo or in-vitro testing.